Solid Biosciences (SLDB) Total Non-Current Liabilities (2018 - 2026)
Quarterly results put Total Non-Current Liabilities at $18.5 million for Q1 2026, down 10.57% from a year ago — trailing twelve months through Mar 2026 was $18.5 million (down 10.57% YoY), and the annual figure for FY2025 was $19.1 million, down 9.93%.
Solid Biosciences has reported Total Non-Current Liabilities over the past 7 years, most recently at $18.5 million for Q1 2026.
- Total Non-Current Liabilities reached $18.5 million in Q1 2026 per SLDB's latest filing, down from $19.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $48.5 million in Q4 2022 and bottomed at $18.5 million in Q1 2026.
- Median Total Non-Current Liabilities over the past 5 years was $20.9 million (2024), compared with a mean of $23.7 million.
- The largest annual shift saw Total Non-Current Liabilities crashed 50.63% in 2023 before it decreased 9.93% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $48.5 million in 2022, then plummeted by 50.63% to $23.9 million in 2023, then fell by 11.62% to $21.2 million in 2024, then decreased by 9.93% to $19.1 million in 2025, then dropped by 3.04% to $18.5 million in 2026.
- Business Quant data shows Total Non-Current Liabilities for SLDB at $18.5 million in Q1 2026, $19.1 million in Q4 2025, and $19.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 18.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.48 Mn |
| Dec 31, 2025 | 19.06 Mn |
| Sep 30, 2025 | 19.62 Mn |
| Jun 30, 2025 | 20.16 Mn |
| Mar 31, 2025 | 20.66 Mn |
| Dec 31, 2024 | 21.16 Mn |
| Sep 30, 2024 | 21.95 Mn |
| Jun 30, 2024 | 23.05 Mn |
| Dec 31, 2023 | 23.94 Mn |
| Dec 31, 2022 | 48.49 Mn |
| Dec 31, 2020 | 37.78 Mn |
| Dec 31, 2018 | 13.34 Mn |
| Sep 30, 2018 | 10.64 Mn |
| Jun 30, 2018 | 8.68 Mn |
| Mar 31, 2018 | 9.93 Mn |